secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0001213900-25-070642
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial shareholders approve authorized share increase, reverse split, and equity plan amendment at 2025 annual meeting
--------------------------------------------------------------------------------

- Approved increase in authorized common stock from 50M to 100M shares, effective August 1, 2025.
- Approved reverse stock split at a ratio of 1-for-2 to 1-for-25, with ratio set by Board.
- Approved Amendment No. 7 to 2017 Equity Plan, increasing reserved shares from 2M to 5M.
- Approved issuance of up to 6.73M shares upon exercise of Series B-1/C-1 warrants from May 2025 offering.
- Approved issuance of up to 19.425M shares upon exercise of Series D/E warrants from June 2025 offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025070642/0001213900-25-070642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025070642/ea0251363-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-070642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer